Skip to main content
Midas Edge

Corvus Pharmaceuticals, Inc.

For the period ended Dec 31, 2025. Filed Mar 12, 2026.

View on SEC.gov

About this filing

A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.

FY2025 · Filed Mar 12, 2026

CRVS$11.37+0.2%Stored close · as of Nov 10, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits
Contents

Consolidated Statements of Stockholders’ Equity

CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS’ EQUITY

(in thousands, except share data)

​​​​​​​​​​​​​​​​​​
​ · ​ · ​ · ​ ​ ​ · ​ · ​ · ​ ​ ​ · ​ · ​ · ​ ​ ​ · Accumulated · ​ ​ ​ · ​ · ​ · ​ ​ ​ · ​ · ​
​ · ​ · ​ · ​ · ​ · ​ · ​ · Additional · ​ · Other · ​ · ​ · ​ · ​ · Total
​ · ​ · Common Stock · ​ · Paid-in · ​ · Comprehensive · ​ · Accumulated · ​ · Stockholders’
​ · ​ · Shares · ​ ​ ​ · Amount · ​ ​ ​ · Capital · ​ ​ ​ · Income (Loss) · ​ ​ ​ · Deficit · ​ ​ ​ · Equity
Balance at December 31, 2022​46,553,511​$5​$364,361​$(563)​$(307,688)​$56,115
Issuance of common stock in connection with at-the-market offering, net​2,461,903​​—​​7,843​​—​​—​​7,843
Common stock issued on exercise of stock options​23,168​​—​​12​​—​​—​​12
Stock-based compensation expense​—​​—​​2,147​​—​​—​​2,147
Unrealized loss on marketable securities​—​​—​​—​​66​​—​​66
Foreign currency translation adjustment​—​​—​​—​​(470)​​—​​(470)
Net loss​—​​—​​—​​—​​(27,029)​​(27,029)
Balance at December 31, 2023​49,038,582​$5​$374,363​$(967)​$(334,717)​$38,684
Common stock issued in connection with registered direct offering, net​13,512,699​​1​​16,404​​—​​—​​16,405
Pre-funded warrants issued in connection with registered direct offering, net​—​​—​​5,031​​—​​—​​5,031
Issuance of common stock upon exercise of common stock warrants​5,311,198​​1​​31,990​​—​​—​​31,991
Common stock issued on exercise of stock options​37,300​​—​​68​​—​​—​​68
Stock-based compensation expense​—​​—​​3,003​​—​​—​​3,003
Unrealized gain on marketable securities​—​​—​​—​​65​​—​​65
Foreign currency translation adjustment​—​​—​​—​​(386)​​—​​(386)
Net loss​—​​—​​—​​—​​(62,293)​​(62,293)
Balance at December 31, 2024​67,899,779​$7​$430,859​$(1,288)​$(397,010)​$32,568
Issuance of common stock upon exercise of common stock warrants​6,330,578​​—​​23,053​​—​​—​​23,053
Issuance of pre-funded warrants upon exercise of common stock warrants​—​​—​​14,461​​—​​—​​14,461
Common stock issued on exercise of stock options​466,272​​—​​684​​—​​—​​684
Stock-based compensation expense​—​​—​​5,330​​—​​—​​5,330
Unrealized loss on marketable securities​—​​—​​—​​(17)​​—​​(17)
Foreign currency translation adjustment​—​​—​​—​​409​​—​​409
Net loss​—​​—​​—​​—​​(15,283)​​(15,283)
Balance at December 31, 2025​74,696,629​$7​$474,387​$(896)​$(412,293)​$61,205
ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.